longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Illumina

ILMN

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 40.74, above the reasonable range, cheaper than 1.53% of the time in the past 1 years, and the industry ranks 13/59, the industry Median -1.55.

40.74xP/E
$222.29Stock price
$5.46Earnings per share
40.74xP/E
Stock price$222.29Earnings per share$5.46

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
27.66x
Typical range
21.75x–33.26x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
011223344

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x40x80x120x160x200x
P/E ratio
Name/Symbol
ILMNUSIllumina
40.74x9.25%$33.57B
WSTUSWest Pharmaceutical
45.47x26.29%$25.69B
BIOUSBio-Rad Lab
45.45x70.13%$10.11B
BIOBBio-Rad Lab-B
43.89x--$9.76B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.